Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
Public ClinicalTrials.gov record NCT00093795. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC→P); DD AC Followed By DD Paclitaxel Plus Gemcitabine (DD AC→PG)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase III trial is studying three different combination chemotherapy regimens and comparing how well they work in treating women who have undergone surgery for node-positive breast cancer.
Study identification
- NCT ID
- NCT00093795
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 4,894 participants
Conditions and interventions
Conditions
Interventions
- Cyclophosphamide Drug
- Docetaxel Drug
- Gemcitabine Drug
- Paclitaxel Drug
- Doxorubicin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2004 (Type not available)
- Primary completion
- Mar 2012 (Actual)
- Completion
- Jun 2016 (Actual)
- Last update posted
- Jan 11, 2018
2004 – 2016
United States locations
- U.S. sites
- 12
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham | Birmingham | Alabama | 35294 | — |
| Providence Cancer Center | Anchorage | Alaska | 99508 | — |
| Robert and Carol Weissman Cancer Center at Martin Memorial | Stuart | Florida | 34994 | — |
| Lucille P. Markey Cancer Center at University of Kentucky | Lexington | Kentucky | 40536-0093 | — |
| South Shore Hospital | South Weymouth | Massachusetts | 02190 | — |
| Methodist Estabrook Cancer Center | Omaha | Nebraska | 68114 | — |
| CCOP - Northern New Jersey | Hackensack | New Jersey | 07601 | — |
| Blumenthal Cancer Center at Carolinas Medical Center | Charlotte | North Carolina | 28232-2861 | — |
| Altru Cancer Center at Altru Hospital | Grand Forks | North Dakota | 58201 | — |
| Community Oncology Group at Cleveland Clinic Cancer Center | Independence | Ohio | 44131 | — |
| Chestnut Hill Healthcare Cancer Center | Philadelphia | Pennsylvania | 19118 | — |
| Madigan Army Medical Center - Tacoma | Tacoma | Washington | 98431 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00093795, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 11, 2018 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00093795 live on ClinicalTrials.gov.